EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders

Adrian Mor, Anna Tankiewicz-Kwedlo iD, Marianna Ciwun, Janina Lewkowicz iD, Dariusz Pawlak iD

Cells · 26.07.2024 · 13 (15) · 1259

DOI: 10.3390/cells13151259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 26.07.2024. Verfasst von Adrian Mor und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacodynamics, Medical University of Bialystok, A. Mickiewicza 2C, 15-222 Bialystok, Poland. Hauptthemen laut MEDLINE: Kynurenine, Inflammation. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 257 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Bialystok, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review discusses the potential of targeting the kynurenine pathway (KP) in the treatment of inflammatory diseases. The KP, responsible for the catabolism of the amino acid tryptophan (TRP), produces metabolites that regulate various physiological processes, including inflammation, cell cycle, and neurotransmission. These metabolites, although necessary to maintain immune balance, may accumulate excessively during inflammation, leading to systemic disorders. Key KP enzymes such as indoleamine 2,3-dioxygenase 1 (IDO1), indoleamine 2,3-dioxygenase 2 (IDO2), tryptophan 2,3-dioxygenase (TDO), and kynurenine 3-monooxygenase (KMO) have been considered promising therapeutic targets. It was highlighted that both inhibition and activation of these enzymes may be beneficial, depending on the specific inflammatory disorder. Several inflammatory conditions, including autoimmune diseases, for which modulation of KP activity holds therapeutic promise, have been described in detail. Preclinical studies suggest that this modulation may be an effective treatment strategy for diseases for which treatment options are currently limited. Taken together, this review highlights the importance of further research on the clinical application of KP enzyme modulation in the development of new therapeutic strategies for inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KynurenineInflammationHumansAnimalsMolecular Targeted TherapyIndoleamine-Pyrrole 2,3,-Dioxygenase

Stichwörter der Autor:innen

immunosuppressionindoleamine 2,3-dioxygenaseinflammatory disorderskynureninekynurenine 3-monooxygenasekynurenine pathwaytryptophantryptophan 2,3-dioxygenase

Substanzen

KynurenineIndoleamine-Pyrrole 2,3,-Dioxygenase

Autor:innen und Institutionen

  • Department of Pharmacodynamics, Medical University of Bialystok, A. Mickiewicza 2C, 15-222 Bialystok, Poland.
  • Department of Internal Medicine and Metabolic Diseases, Medical University of Bialystok, M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland.

ORCID-Profile: Anna Tankiewicz-Kwedlo, Janina Lewkowicz, Dariusz Pawlak

Förderung

  • Medical University of Bialystok, Poland

Zitieren

APA

Mor, A., Tankiewicz-Kwedlo, A., Ciwun, M., Lewkowicz, J., & Pawlak, D. (2024). Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders. Cells, 13(15), 1259. https://doi.org/10.3390/cells13151259

Vancouver

Mor A, Tankiewicz-Kwedlo A, Ciwun M, Lewkowicz J, Pawlak D. Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders. Cells. 2024;13(15):1259. doi:10.3390/cells13151259

BibTeX
@article{Mor2024,
  author = {Mor, Adrian and Tankiewicz-Kwedlo, Anna and Ciwun, Marianna and Lewkowicz, Janina and Pawlak, Dariusz},
  title = {Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {15},
  pages = {1259},
  doi = {10.3390/cells13151259}
}
Kostenlos starten →